• The reasons why antibiotic treatment may be

  2024-09-13

  

  The reasons why antibiotic treatment may be detrimental are diverse. First, it may result in disruption of multifaceted microbe–microbe, as well as microbe–host, interactions that are key for the maintenance of homeostasis within this ecosystem. This can lead to the expansion of pathogenic microorga

• Most clinically approved antiangiogenic drugs

  2024-09-13

  

  Most clinically approved antiangiogenic drugs are aimed at blocking the action of vascular endothelial growth factor, or VEGF, which is accepted to be the most important tumor-derived angiogenic factor, stimulating proliferation and migration of endothelial cells, as well as branching of vessels (Fe

• The efficacy of antibiotics in improving smell function has

  2024-09-13

  

  The efficacy of gallic acid in improving smell function has been previously found to be negative, both when used for bacterial and viral infections. Van Zele et al, in a double-blind, placebo-controlled, multicenter study, found no influence of doxycycline treatment on self-reported olfactory loss i

• br Antiangiogenic therapy in non small cell lung cancer

  2024-09-13

  

  Antiangiogenic therapy in non-small cell lung cancer (NSCLC) Antiangiogenic targeted therapy is an area of active research in which numerous agents have been studied and have been shown to be effective for many tumor types including NSCLC. Angiogenesis is frequently upregulated in malignant solid

• It has been well established that shortly after

  2024-09-13

  

  It has been well established that shortly after systemic inflammation, NADPH oxidase and iNOS activity were increased in the Picroside II and lead to overproduction of reactive oxygen species (ROS) and NO [66]. Moreover, previous studies indicated that Ang II induced an increased level of NADPH oxid

• Numerous epidemiological studies document fewer cardiovascul

  2024-09-13

  

  Numerous epidemiological studies document fewer cardiovascular events and increased survival of non-CKD individuals treated with angiotensin-converting enzyme inhibitors/angiotensin receptor blockers (ACEI/ARBs) [8], [9]. By contrast, there are few studies of cardiovascular benefits of interruption

• Discussion The present experiments follow up

  2024-09-13

  

  Discussion The present experiments follow-up and are completely consistent with our prior findings [26] that blood Aβ is subject to peripheral clearance by a major pathway for circulating pathogens in primates, immune adherence [30,31]. CR1-mediated erythrocyte immune adherence, as well as CR1-medi

• Here we provide evidence that NO contributes to changes

  2024-09-13

  

  Here, we provide evidence that NO contributes to changes in synaptic strength, but also offer an explanation as to why previous attempts to link NO to LTP have often failed. Our results describe a model by which cycling AMPARs, held in intracellular pools, are rapidly delivered to the membrane surfa

• The rescue of the behavioral deficit was

  2024-09-13

  

  The rescue of the behavioral deficit was associated with a significant reduction in the levels of both soluble and insoluble Aβ peptides and their deposition in the d-glucose of the same animals. In search for the mechanism behind the reduced amyloidosis, we assessed APP metabolism. Confirming prev

• br Development of lorlatinib from crizotinib to a clinical

  2024-09-12

  

  Development of lorlatinib from crizotinib (1) to a clinical candidate (6) Xalkori (1, PF-02341066, crizotinib), was the first-in-class ALK inhibitor approved by the Unites States Food and Drug Administration (FDA) in 2011 as a first-line treatment for ALK+- NSCLC patients. This section describes

• The major strength of this

  2024-09-12

  

  The major strength of this study is the large sample size which increases the statistical power to detect the likely subtle differences in peripheral methylation observed in psychiatric disorders (Olsson et al., 2010). Larger studies help provide more robust estimates of true associations, as small

• Prostate cancer is the second leading cause of

  2024-09-12

  

  Prostate cancer is the second leading cause of cancer-related death in men in the United States [25]. Similar to pancreatic cancer, prostate cancer has few diagnostic options available, particularly to differentiate indolent from aggressive disease. Axl is also overexpressed in ∼50% of prostate canc

• CB-5083 br Conclusion br List of abbreviations br Acknowledg

  2024-09-12

  

  Conclusion List of abbreviations Acknowledgment The studies performed by our laboratory and presented in this review were supported by the Ministry of Education, Culture, Sports, Science and Technology of Japan, (KAKENHI 17590618 [to H.I.] and KAKENHI 22249017 [to Y.Y.]), and the Japanese

• Previous studies have demonstrated that the expression of th

  2024-09-12

  

  Previous studies have demonstrated that the expression of the Aurora B gene is maximally increased at G2/M phage during mitosis (Honda et al., 2003, Fu et al., 2007, Goldenson and Crispino, 2015), and exhibits an extraordinary upregulation in a number of human cancers (Fu et al., 2007, Kollareddy et

• Previous studies have demonstrated ATR inhibition is effecti

  2024-09-12

  

  Previous studies have demonstrated ATR inhibition is effective for treating cancers combining with chemotherapies in lung adenocarcinoma, gastric cancer, HER2 positive breast cancer and chronic lymphocytic leukemia Fer-1 to enhance chemotherapy sensitivity [[16], [17], [18],[20], [21], [22]]. VE-82

16067 records 110/1072 page Previous Next First page 上5页 106107108109110 下5页 Last page